Human FGF-23 PharmaGenie ELISA Kit (SBRS0575)

Assay Genie's immunoassay targets the intact 32 kDa endocrine factor that suppresses renal 1-alpha-hydroxylase activity, supporting investigations into phosphate wasting disorders, autosomal dominant hypophosphatemic rickets, and tumor-induced osteomalacia. The capture antibody binds the N-terminal region of FGF-23 with no significant cross-reactivity toward FGF-19 or FGF-21 family members. Reconstituted lyophilized standards are stable for up to 14 days refrigerated, while unreconstituted components should be frozen at -20 °C for long-term retention. Researchers handling longitudinal CKD-MBD cohorts typically aliquot plasma within 30 minutes of collection to limit proteolytic cleavage of the intact hormone by prohormone convertases. The protocol uses an in vitro two-step incubation with streptavidin-HRP conjugate and TMB substrate, terminating with a stop solution for measurement. Each plate accommodates up to 40 duplicate samples alongside a seven-point standard curve, and the assay has been cited in publications examining pediatric X-linked hypophosphatemia and dialysis-associated cardiac hypertrophy outcomes.